Evidence map›Paper›PMID 36632155›Full record

ArticleTranslational andrology and urology2022

A lncRNA-immune checkpoint-related gene signature predicts metastasis-free survival in prostate adenocarcinoma.

Chen Ye, Shengfei Qin, Shuang Qiu, Lin Zhao, Jiaying Miao, Yuangui Chen, Tie Zhou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational andrology and urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chen Ye *Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Shengfei Qin *Department of Urology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Shuang Qiu *Department of Nuclear Medicine, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Lin ZhaoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Jiaying MiaoDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Yuangui ChenDepartment of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, China.
Tie ZhouDepartment of Urology, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The 5-year overall survival rate in metastatic prostate adenocarcinoma (PRAD) is extremely low. Genomic studies of PRAD have improved our understanding of disease biology. However, the role of immune checkpoint genes (ICGs) in PRAD remains unclear. Methods: Univariate and multivariate analyses were used to analyze genes associated with metastasis-free survival (MFS) in The Cancer Genome Atlas (TCGA)-PRAD dataset. The expressions of Results: In our study, univariate and multivariate analyses revealed that the mRNA expressions of two ICGs, Conclusions: Our results provide new targets for predicting tumor metastasis in PRAD and treating patients with metastatic PRAD.

Indexed as

immune checkpoint genes (ICGs)long non-coding RNA (lncRNA)Metastatic prostate adenocarcinoma (metastatic PRAD)

Identifiers

PMID36632155
PMCPMC9827409

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.